Additionally, TNBC has higher immunogenicity, more tumor-infiltrating lymphocytes, and increased PD-L1 expression compared to other breast cancer subtypes, making it more amenable to immune checkpoint blockade therapies (24). Here, CD274 is linked to breast carcinoma.